Your browser doesn't support javascript.
loading
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.
Baeten, Jared M; Heffron, Renee; Kidoguchi, Lara; Mugo, Nelly R; Katabira, Elly; Bukusi, Elizabeth A; Asiimwe, Stephen; Haberer, Jessica E; Morton, Jennifer; Ngure, Kenneth; Bulya, Nulu; Odoyo, Josephine; Tindimwebwa, Edna; Hendrix, Craig; Marzinke, Mark A; Ware, Norma C; Wyatt, Monique A; Morrison, Susan; Haugen, Harald; Mujugira, Andrew; Donnell, Deborah; Celum, Connie.
Afiliação
  • Baeten JM; Department of Global Health, University of Washington, Seattle, Seattle, Washington, United States of America.
  • Heffron R; Department of Medicine, University of Washington, Seattle, Seattle, Washington, United States of America.
  • Kidoguchi L; Department of Epidemiology, University of Washington, Seattle, Seattle, Washington, United States of America.
  • Mugo NR; Department of Global Health, University of Washington, Seattle, Seattle, Washington, United States of America.
  • Katabira E; Department of Epidemiology, University of Washington, Seattle, Seattle, Washington, United States of America.
  • Bukusi EA; Department of Global Health, University of Washington, Seattle, Seattle, Washington, United States of America.
  • Asiimwe S; Department of Global Health, University of Washington, Seattle, Seattle, Washington, United States of America.
  • Haberer JE; Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
  • Morton J; Infectious Disease Institute, Makerere University, Kampala, Uganda.
  • Ngure K; Department of Global Health, University of Washington, Seattle, Seattle, Washington, United States of America.
  • Bulya N; Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
  • Odoyo J; Kabwohe Clinical Research Center, Kabwohe, Uganda.
  • Tindimwebwa E; Massachusetts General Hospital, Boston, Massachusetts, United States of America.
  • Hendrix C; Department of Global Health, University of Washington, Seattle, Seattle, Washington, United States of America.
  • Marzinke MA; College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
  • Ware NC; Infectious Disease Institute, Makerere University, Kampala, Uganda.
  • Wyatt MA; Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
  • Morrison S; Kabwohe Clinical Research Center, Kabwohe, Uganda.
  • Haugen H; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
  • Mujugira A; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
  • Donnell D; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Celum C; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
PLoS Med ; 13(8): e1002099, 2016 08.
Article em En | MEDLINE | ID: mdl-27552090
BACKGROUND: Antiretroviral-based interventions for HIV-1 prevention, including antiretroviral therapy (ART) to reduce the infectiousness of HIV-1 infected persons and pre-exposure prophylaxis (PrEP) to reduce the susceptibility of HIV-1 uninfected persons, showed high efficacy for HIV-1 protection in randomized clinical trials. We conducted a prospective implementation study to understand the feasibility and effectiveness of these interventions in delivery settings. METHODS AND FINDINGS: Between November 5, 2012, and January 5, 2015, we enrolled and followed 1,013 heterosexual HIV-1-serodiscordant couples in Kenya and Uganda in a prospective implementation study. ART and PrEP were offered through a pragmatic strategy, with ART promoted for all couples and PrEP offered until 6 mo after ART initiation by the HIV-1 infected partner, permitting time to achieve virologic suppression. One thousand thirteen couples were enrolled, 78% of partnerships initiated ART, and 97% used PrEP, during a median follow-up of 0.9 years. Objective measures of adherence to both prevention strategies demonstrated high use (≥85%). Given the low HIV-1 incidence observed in the study, an additional analysis was added to compare observed incidence to incidence estimated under a simulated counterfactual model constructed using data from a prior prospective study of HIV-1-serodiscordant couples. Counterfactual simulations predicted 39.7 HIV-1 infections would be expected in the population at an incidence of 5.2 per 100 person-years (95% CI 3.7-6.9). However, only two incident HIV-1 infections were observed, at an incidence of 0.2 per 100 person-years (95% CI 0.0-0.9, p < 0.0001 versus predicted). The use of a non-concurrent comparison of HIV-1 incidence is a potential limitation of this approach; however, it would not have been ethical to enroll a contemporaneous population not provided access to ART and PrEP. CONCLUSIONS: Integrated delivery of time-limited PrEP until sustained ART use in African HIV-1-serodiscordant couples was feasible, demonstrated high uptake and adherence, and resulted in near elimination of HIV-1 transmission, with an observed HIV incidence of <0.5% per year compared to an expected incidence of >5% per year.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV / Profilaxia Pré-Exposição Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Região como assunto: Africa Idioma: En Revista: PLoS Med Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV / Profilaxia Pré-Exposição Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies País/Região como assunto: Africa Idioma: En Revista: PLoS Med Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos